The University of Southampton
University of Southampton Institutional Repository

Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants

Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants
Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants
Pleasurable sexual activity is an essential component of many human relationships, providing a sense of physical, psychological, and social well-being. Epidemiological and clinical studies show that depressive symptoms and depressive illness are associated with impairments in sexual function and satisfaction, both in untreated and treated patients. The findings of randomized placebo-controlled trials demonstrate that most of the currently available antidepressant drugs are associated with the development or worsening of sexual dysfunction, in a substantial proportion of patients. Sexual difficulties during antidepressant treatment often resolve as depression lifts but can endure over long periods and may reduce self-esteem and affect mood and relationships adversely. Sexual dysfunction during antidepressant treatment is typically associated with many possible causes, but the risk and type of dysfunction vary with differing compounds and should be considered when making decisions about the relative merits and drawbacks of differing antidepressants. A range of interventions can be considered when managing patients with sexual dysfunction associated with antidepressants, including the prescription of phosphodiesterase-5 inhibitors, but none of these approaches can be considered "ideal." As treatment-emergent sexual dysfunction is less frequent with certain drugs, presumably related to differences in their pharmacological properties, and because current management approaches are less than ideal, a reduced burden of treatment-emergent sexual dysfunction represents a tolerability target in the development of novel antidepressants.

2090-1321
256841
Baldwin, D.S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Palazzo, M.C.
bb51cbd3-aa35-4d4e-a0ea-0930a1c2151e
Masdrakis, V.G.
67ff5fb9-fbf9-4d50-a495-7bf3f4200771
Baldwin, D.S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Palazzo, M.C.
bb51cbd3-aa35-4d4e-a0ea-0930a1c2151e
Masdrakis, V.G.
67ff5fb9-fbf9-4d50-a495-7bf3f4200771

Baldwin, D.S., Palazzo, M.C. and Masdrakis, V.G. (2013) Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. Depression Research and Treatment, 2013, 256841. (doi:10.1155/2013/256841). (PMID:23431429)

Record type: Article

Abstract

Pleasurable sexual activity is an essential component of many human relationships, providing a sense of physical, psychological, and social well-being. Epidemiological and clinical studies show that depressive symptoms and depressive illness are associated with impairments in sexual function and satisfaction, both in untreated and treated patients. The findings of randomized placebo-controlled trials demonstrate that most of the currently available antidepressant drugs are associated with the development or worsening of sexual dysfunction, in a substantial proportion of patients. Sexual difficulties during antidepressant treatment often resolve as depression lifts but can endure over long periods and may reduce self-esteem and affect mood and relationships adversely. Sexual dysfunction during antidepressant treatment is typically associated with many possible causes, but the risk and type of dysfunction vary with differing compounds and should be considered when making decisions about the relative merits and drawbacks of differing antidepressants. A range of interventions can be considered when managing patients with sexual dysfunction associated with antidepressants, including the prescription of phosphodiesterase-5 inhibitors, but none of these approaches can be considered "ideal." As treatment-emergent sexual dysfunction is less frequent with certain drugs, presumably related to differences in their pharmacological properties, and because current management approaches are less than ideal, a reduced burden of treatment-emergent sexual dysfunction represents a tolerability target in the development of novel antidepressants.

Text
DRT2013-256841[1].pdf - Other
Download (550kB)

More information

Published date: 2013
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 367930
URI: http://eprints.soton.ac.uk/id/eprint/367930
ISSN: 2090-1321
PURE UUID: ee51146a-a4e9-4f37-a3e4-485198048593
ORCID for D.S. Baldwin: ORCID iD orcid.org/0000-0003-3343-0907

Catalogue record

Date deposited: 26 Aug 2014 16:14
Last modified: 18 Feb 2021 16:44

Export record

Altmetrics

Contributors

Author: D.S. Baldwin ORCID iD
Author: M.C. Palazzo
Author: V.G. Masdrakis

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×